Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRIM28 interacting DNA damage repair enhancing non-coding transcript (TRIDENT)
- Target
- TRIDENT
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
TRIM28 interacting DNA damage repair enhancing non-coding transcript (TRIDENT) is a long non-coding RNA whose expression is upregulated by epidermal growth factor receptor (EGFR) activation, particularly in EGFR-driven non-small cell lung cancer. TRIDENT interacts with the protein TRIM28 and promotes its phosphorylation, which facilitates efficient repair of DNA damage in cancer cells. Knockdown of TRIDENT results in decreased tumor cell proliferation and increased sensitivity to multiple chemotherapeutic drugs. TRIDENT therefore represents a potential therapeutic target for overcoming drug resistance in certain cancers, as well as a possible biomarker for drug-resistant, EGFR-driven malignancies[5][3]. No drugs are currently known to directly target TRIDENT, but its inhibition sensitizes tumors to existing chemotherapies.
- Other names
- RP11-462G12.2TRIDENTTRIM28 Interacting DNA damage repair Enhancing Noncoding TranscriptLINC02861long intergenic non-protein coding RNA 2861TRIDDENT
02
Mechanism of action
Promotes phosphorylation of TRIM28, facilitating efficient DNA repair and contributing to drug resistance[5]
03
Biological functions
Enhancing DNA damage repairModulation of TRIM28 phosphorylationPromotion of cell proliferationRegulation of chemotherapeutic sensitivity in cancer
04
Disease associations
CancerDrug resistance
05
Safety considerations
Targeting TRIDENT may induce DNA damage accumulation in non-cancerous tissues, with possible toxicity to proliferating normal cells (inferred from its role in DNA repair)[5]Further preclinical safety data are not yet available
06
Interacting drugs
None directly reported; knockdown sensitizes to chemotherapeutics in cancer models
07
Biomarkers
TRIDENT expression as a potential biomarker for EGFR-driven non-small cell lung cancer and for drug resistance status[5]
Beyond the preview
Go deeper on TRIM28 interacting DNA damage repair enhancing non-coding transcript (TRIDENT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRIM28 interacting DNA damage repair enhancing non-coding transcript (TRIDENT).